Testing a blood test to help diagnose Alzheimer's disease in primary care
Tests how accurately a blood test identifies Alzheimer's disease in general practice patients.
Plain-language title generated from the registry record
Registry title: Blood-based Biomarkers for Diagnosis of Alzheimer's
Key facts
- Where
- Stavanger, NorwaySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 100 years old?
Source: NCT05187819, who can take part
Where in Norway
- Stavanger University HospitalStavanger, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Helse Stavanger HF
- Trial code
- NCT05187819
- Record updated
- 28 September 2023
- Original description
Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET). These diagnostic procedures are highly accurate, but the high cost and low availability hamper their feasibility. Recently, ultrasensitive blood tests predicting Alzheimer pathologies in the brain have been developed. These tests have a reliable ability to differentiate AD from other neurodegenerative disorders and identify AD across the clinical continuum with high sensitivity and specificity in research cohorts with a high prevalence of AD.Read full original descriptionShow less
Accuracy of Blood-based Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice
Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET). These diagnostic procedures are highly accurate, but the high cost and low availability hamper their feasibility. Recently, ultrasensitive blood tests predicting Alzheimer pathologies in the brain have been developed. These tests have a reliable ability to differentiate AD from other neurodegenerative disorders and identify AD across the clinical continuum with high sensitivity and specificity in research cohorts with a high prevalence of AD.
This project will assess the predictive value of these tests in a general practice population.
The hypothesis is that the actual blood panel will have high positive predictive value for a diagnosis of Alzheimer's disease in the primary health care setting.
Inclusion: Participants suspected by their GP to have possible dementia, based on history, clinical examination and/or cognitive screening.
Exclusion: Severe psychiatric disease, use of medication or physical disease that according to the GP may affect participation or likely contribute significantly to the observed cognitive impairment; Lack of capacity for consent as judged by the GP; Patients not wanting to be referred to the memory outpatient clinic.